67 related articles for article (PubMed ID: 1658138)
1. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects.
Richards AM; Wittert G; Espiner EA; Yandle TG; Frampton C; Ikram H
J Hypertens; 1991 Oct; 9(10):955-62. PubMed ID: 1658138
[TBL] [Abstract][Full Text] [Related]
2. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure.
Richards AM; Crozier IG; Espiner EA; Ikram H; Yandle TG; Kosoglou T; Rallings M; Frampton C
J Cardiovasc Pharmacol; 1992; 20(5):735-41. PubMed ID: 1280735
[TBL] [Abstract][Full Text] [Related]
3. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Richards AM; Wittert GA; Crozier IG; Espiner EA; Yandle TG; Ikram H; Frampton C
J Hypertens; 1993 Apr; 11(4):407-16. PubMed ID: 8390508
[TBL] [Abstract][Full Text] [Related]
4. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
Kimmelstiel CD; Perrone R; Kilcoyne L; Souhrada J; Udelson J; Smith J; de Bold A; Griffith J; Konstam MA
Cardiology; 1996; 87(1):46-53. PubMed ID: 8631044
[TBL] [Abstract][Full Text] [Related]
5. The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.
Jardine AG; Connell JM; Northridge D; Dilly SG; Cussans NJ; Davidson G; Doyle J; Leckie BL; Lever AF
Am J Hypertens; 1990 Sep; 3(9):661-7. PubMed ID: 2145871
[TBL] [Abstract][Full Text] [Related]
6. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers.
Richards AM; Wittert GA; Espiner EA; Yandle TG; Ikram H; Frampton C
Circ Res; 1992 Dec; 71(6):1501-7. PubMed ID: 1423942
[TBL] [Abstract][Full Text] [Related]
7. EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide.
Richards AM; Wittert G; Espiner EA; Yandle TG; Frampton C; Ikram H
J Clin Endocrinol Metab; 1991 Jun; 72(6):1317-22. PubMed ID: 1827451
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats.
Hirata Y; Suzuki E; Hayakawa H; Matsuoka H; Sugimoto T; Kangawa K; Matsuo H
J Cardiovasc Pharmacol; 1994 Feb; 23(2):283-90. PubMed ID: 7511759
[TBL] [Abstract][Full Text] [Related]
9. [Effect of sinorphan, an endopeptidase inhibitor on severe congestive cardiac insufficiency].
Varin J; Duboc D; Weber S; Fouchard J; Schwartz JC; Muffat-Joly M; Guérin F
Arch Mal Coeur Vaiss; 1991 Oct; 84(10):1465-71. PubMed ID: 1662033
[TBL] [Abstract][Full Text] [Related]
10. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man.
O'Connell JE; Jardine AG; Davies DL; McQueen J; Connell JM
Clin Sci (Lond); 1993 Jul; 85(1):19-26. PubMed ID: 8149689
[TBL] [Abstract][Full Text] [Related]
11. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia.
Chodjania Y; Tharaux PL; Ragueneau I; Dussaule JC; Picker JL; Funck-Brentano C; Jaillon P
Clin Pharmacol Ther; 2002 Jun; 71(6):468-78. PubMed ID: 12087350
[TBL] [Abstract][Full Text] [Related]
12. Effects of atrial natriuretic factor on natriuresis and cGMP in patients with essential hypertension.
Cusson JR; Hamet P; Gutkowska J; Kuchel O; Genest J; Cantin M; Larochelle P
J Hypertens; 1987 Aug; 5(4):435-43. PubMed ID: 2822796
[TBL] [Abstract][Full Text] [Related]
13. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
O'Connell JE; Jardine AG; Davidson G; Connell JM
J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
[TBL] [Abstract][Full Text] [Related]
14. The role of neutral endopeptidase in dogs with evolving congestive heart failure.
Margulies KB; Barclay PL; Burnett JC
Circulation; 1995 Apr; 91(7):2036-42. PubMed ID: 7895362
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular, renal and endocrine responses to low doses of atrial natriuretic factor in mild essential hypertension.
Cusson JR; Thibault G; Kuchel O; Hamet P; Cantin M; Larochelle P
J Hum Hypertens; 1989 Apr; 3(2):89-96. PubMed ID: 2547952
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure.
Northridge DB; Jardine AG; Findlay IN; Archibald M; Dilly SG; Dargie HJ
Am J Hypertens; 1990 Sep; 3(9):682-7. PubMed ID: 2145874
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects.
Richards M; Espiner E; Frampton C; Ikram H; Yandle T; Sopwith M; Cussans N
Hypertension; 1990 Sep; 16(3):269-76. PubMed ID: 2144260
[TBL] [Abstract][Full Text] [Related]
18. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
Seymour AA; Asaad MM; Lanoce VM; Langenbacher KM; Fennell SA; Rogers WL
J Pharmacol Exp Ther; 1993 Aug; 266(2):872-83. PubMed ID: 8394922
[TBL] [Abstract][Full Text] [Related]
19. Relationship between natriuresis and changes in plasma atrial natriuretic factor, renin activity and aldosterone levels in fasting obese subjects.
Donckier JE; Kolanowski J; Berbinschi A; Gerard G; Ketelslegers JM
Diabete Metab; 1990; 16(4):278-83. PubMed ID: 2148294
[TBL] [Abstract][Full Text] [Related]
20. Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure.
Lipkin GW; Dawnay AB; Harwood SM; Cattell WR; Raine AE
Kidney Int; 1997 Sep; 52(3):792-801. PubMed ID: 9291201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
